Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 16;11:686972. doi: 10.3389/fonc.2021.686972

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Wang, Li, Liao, Li, Dong, Peng, Xu, Fan, Gao, Liu, Liu and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Calibration curves for 1-, 3- and 5-year overall survival of combined hepatocellular carcinoma and cholangiocarcinoma patients in the training cohort and validation cohort. (A) Calibration curves for 1-year overall survival of combined hepatocellular carcinoma and cholangiocarcinoma patients in the training cohort; (B) Calibration curves for 3-year overall survival of combined hepatocellular carcinoma and cholangiocarcinoma patients in the training cohort; (C) Calibration curves for 5-year overall survival of combined hepatocellular carcinoma and cholangiocarcinoma patients in the training cohort; (D) Calibration curves for 1-year overall survival of combined hepatocellular carcinoma and cholangiocarcinoma patients in the validation cohort; (E) Calibration curves for 3-year overall survival of combined hepatocellular carcinoma and cholangiocarcinoma patients in the validation cohort; (F) Calibration curves for 5-year overall survival of combined hepatocellular carcinoma and cholangiocarcinoma patients in the validation cohort.